Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
4.940
+0.070 (1.44%)
At close: Mar 4, 2026, 4:00 PM EST
5.82
+0.88 (17.81%)
Pre-market: Mar 5, 2026, 5:44 AM EST
Niagen Bioscience Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Niagen Bioscience stock have an average target of 16.33, with a low estimate of 12 and a high estimate of 23. The average target predicts an increase of 230.57% from the current stock price of 4.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Niagen Bioscience stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +183.40% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +142.91% | Aug 11, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $16 | Strong Buy | Maintains | $13 → $16 | +223.89% | Jun 10, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $10 → $23 | Strong Buy | Maintains | $10 → $23 | +365.59% | Jun 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +163.16% | May 27, 2025 |
Financial Forecast
Revenue This Year
129.84M
from 99.60M
Increased by 30.37%
Revenue Next Year
156.28M
from 129.84M
Increased by 20.36%
EPS This Year
0.19
from 0.11
Increased by 68.76%
EPS Next Year
0.30
from 0.19
Increased by 62.09%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 135.0M | 162.8M | ||
| Avg | 129.8M | 156.3M | ||
| Low | 123.6M | 148.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 35.5% | 25.3% | ||
| Avg | 30.4% | 20.4% | ||
| Low | 24.1% | 14.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.20 | 0.40 | ||
| Avg | 0.19 | 0.30 | ||
| Low | 0.17 | 0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 81.4% | 114.9% | ||
| Avg | 68.8% | 62.1% | ||
| Low | 51.5% | 21.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.